Chris Beaver joins Pharmanet as Director, Immunochemistry Services
PharmaNet Development Group, Inc. announced that Chris Beaver, PhD has joined the Company as Director, immunochemistry services. Dr. Beaver is responsible for leading the immunochemistry team within the Company’s bioanalytical laboratories and expanding its large molecule services, including assay development and sample analysis for biomarker, ELISA, radioimmunoassays, immunogenicity and cell-based assays.
Dr. Beaver’s appointment strengthens PharmaNet’s offerings in large molecule bioanalytical services to support the growing interest in biologics and biosimilars within the pharmaceutical industry. PharmaNet has two GLP-compliant bioanalytical laboratories which are located in Princeton, New Jersey and Quebec City, Canada.
Previously, Dr. Beaver served as Scientific Director of Ligand Binding/Cell Based Assays at another clinical research organization with macromolecule bioanalysis operations. He completed his Ph.D. in Neuroscience at Dalhousie University in Halifax, Canada, followed by post-doctoral training at Yale University. Dr. Beaver is published in multiple scientific publications, including Drug Discovery World and Nature Neuroscience.
Other news from the department people
These products might interest you

Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation

Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.

Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.
Last viewed contents
'Dry eye' linked to chronic pain syndromes
New stem cell strategy aids heart regeneration after heart attack

Novel tools for biomedical applications: Bacterial magnetic nanoparticles - Developed and optimised a process for the isolation and purification of these particles from bacterial cells
A decade of refinements in marrow and stem cell transplantation improves long-term survival of blood cancers

Coat of proteins makes viruses more infectious and links them to Alzheimer's disease

Automated, cost-effective production of mRNA vaccines as well as cell and gene therapeutics - “The system will enable automated, component-based, flexible and validatable production”
Montezuma's_Revenge_(illness)
Fermentation research groups start the worldwide research challenge “BlueCompetition”

Breakthrough for an Alternative to Crude Oil & Palm Oil - OLIPI Receives €1.8 Million Seed Funding for Further Development of CO2-Neutral Climate Oil

Why words become harder to remember as we get older
Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
